Xenon Pharmaceuticals Inc. reported that its Phase 3 X‑TOLE2 study of azetukalner in patients with focal onset seizures met its primary endpoint. The randomized trial enrolled 380 participants, with 374 included in the safety and efficacy analyses. In the 25 mg dose group, the placebo‑adjusted median percentage change in monthly seizure frequency was –42.7 %, and 54.8 % of patients achieved at least a 50 % reduction in seizure frequency, compared with 20.8 % in the placebo arm.
The 25 mg group also outperformed the 15 mg group and the placebo arm, and the Phase 3 results represent a clear improvement over the Phase 2b X‑TOLE study, which reported a –34.6 % median change. The higher efficacy in the larger, more mature Phase 3 cohort underscores the robustness of the drug’s therapeutic effect.
Safety and tolerability were consistent with earlier trials. The most common treatment‑emergent adverse events were dizziness, headache, somnolence and fatigue. No new safety signals were identified, and the overall safety profile remained favorable.
Azetukalner is the first Kv7 potassium channel opener in late‑stage development for epilepsy, positioning it as a potential first‑in‑class therapy. Xenon plans to file a New Drug Application with the U.S. Food and Drug Administration in the third quarter of 2026. If approved, azetukalner could capture a significant share of the estimated $10 billion epilepsy market and may achieve peak sales in the billions, according to analyst projections.
"We are very happy to announce these data for azetukalner, which exceeded expectations and, to our knowledge, show the highest placebo‑adjusted efficacy ever observed in a pivotal epilepsy study," said Xenon’s Chief Medical Officer. "Epilepsy is one of the most common neurological diseases, and foundational antiseizure medications do not provide sufficient seizure control for up to 50 % of patients, so we are very optimistic about the opportunity for azetukalner to meaningfully shift the epilepsy treatment paradigm."
Xenon remains a clinical‑stage biopharmaceutical company that has raised capital to extend its cash runway into the second half of 2027. While the company reported a net loss of $105.26 million for Q4 2025, the focus remains on advancing azetukalner through regulatory approval and establishing a commercial foothold in a large, unmet‑needs market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.